Sirona Biochem Corp. (V:SBM*CA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: Sirona Biochem Corp. (c/o WeWork)
595 Burrard St.
Tel: N/A
IR: See website
Key People
Howard Verrico
Chairman of the Board, Interim Chief Executive Officer, Founder, Secretary
Christopher D. Hopton
Chief Financial Officer, Director
Geraldine Deliencourt-Godefroy
Chief Scientific Officer, Director
Attila Hajdu
Chief Business Development Officer
Business Overview
Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.
Financial Overview
For the six months ended 30 April 2020, Sirona Biochem Corp revenues decreased 99% to C$1K. Net loss increased 34% to C$2.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Share-based payments increase from C$199K to C$1.8M (expense), Legal fees increase from C$2K to C$40K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $48.73M as of Apr 30, 2020
Annual revenue (TTM): $0.07M as of Apr 30, 2020
EBITDA (TTM): -$5.76M as of Apr 30, 2020
Net annual income (TTM): -$5.20M as of Apr 30, 2020
Free cash flow (TTM): -$2.66M as of Apr 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 226,309,320 as of Apr 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.